The Claim
In patients with mild Alzheimer’s disease, treatment with laromestrocel is associated with a statistically significant reduction in serum levels of soluble TIE2 (sTIE2) at weeks 4, 8, and 16 compared to placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with mild Alzheimer’s disease, laromestrocel treatment is linked to lower levels of soluble TIE2 in the blood at weeks 4, 8, and 16 compared to those receiving a placebo.
See the scientific wording
In patients with mild Alzheimer’s disease, laromestrocel treatment is associated with a statistically significant reduction in serum levels of soluble TIE2 (sTIE2), a biomarker of vascular endothelial dysfunction, at weeks 4, 8, and 16 compared to placebo, suggesting potential vascular target engagement.
Laromestrocel releases molecules that stop a specific enzyme from cutting a key receptor off the surface of blood vessel cells in the brain. This keeps the receptor active on the cell surface, which strengthens the blood-brain barrier and reduces inflammation in brain tissue. As a result, less of the cut receptor enters the bloodstream, and brain cells are better protected from damage.
What the research says
1 studyLaromestrocel, a stem cell treatment, helped reduce a blood marker linked to damaged blood vessels in the brains of people with early Alzheimer’s, suggesting it may be protecting their brain’s blood supply.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.